🧪 TrialInsufficient
Registered Phase 4 interventional trial (not yet recruiting). Prediabetes affects millions of adults worldwide and carries a high risk of progression to type 2 diabetes. Mazdutide is a once-weekly injectable drug that activates both GLP-1 and glucagon receptors, lowering blood sugar and body weight simultaneously. This study (DREAM-PRE) tests whether mazdutide can help adults with prediabetes return to normal blood sugar levels. Approximately 150 adults aged 18-75 years with prediabetes and BMI ≥22 kg/m² will be randomly assigned in equal numbers to one of three groups: mazdutide 4 mg once wee
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (not yet recruiting). This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (recruiting). The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift. •The duration of this study is 3 months. This includes: * Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle. * Two health assessments
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (not yet recruiting). Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the eff
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (recruiting). Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes. The aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and s
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (active not recruiting). The goal of this clinical trial is to learn whether a mindfulness-based nutrition group program is feasible and acceptable for adults with obesity who are taking GLP-1 receptor agonist medication and receiving usual medical care, including dietetic counselling. The main questions this study aims to answer are: Can this group program be successfully carried out with adults receiving GLP-1 treatment? Do participants find the program useful, acceptable, and manageable? Are participants willing to attend the sessions, complete the home e
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (recruiting). This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity. 200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 1/Phase 2 interventional trial (recruiting). Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited. Growing evidence suggests that inflammation in the brain and the body plays a key role in the onset and progression of AD. In particular, immune cells called regulatory T cells (Tregs), which normally help control inflammation, are impaired in AD individuals. This leads to increased activity of harmful immune pathways that worsen brain injury. Interleukin-2 (IL-2) i
ClinicalTrials.gov · Jun 2026View trial ↗ InsufficientPreprint
This bibliometric study compared the 100 most-cited articles on GLP-1 receptor agonists (GLP-1RA) with the 100 most-cited articles on metabolic bariatric surgery (MBS), using the Bibliometrix software to analyze citation patterns, journal distribution, and journal impact factors (IF). The study found that GLP-1RA articles accumulated more total citations (91,660 vs. 72,243) and had a higher median citation count (718 vs. 551) than MBS articles. GLP-1RA research was also more internationally collaborative (57% vs. 26%) and appeared more frequently in journals with IF above 40 (41% vs. 25%). The weighted 5-year mean IF was substantially higher for GLP-1RA journals (35.4 vs. 21.6). The authors argue that these differences may reflect a "prestige-journal effect," whereby GLP-1RA trials' placement in flagship journals such as the NEJM and Lancet inflates citation counts relative to MBS research, which is more dispersed across surgical specialty journals. A key limitation is that this study analyzes publication patterns rather than clinical outcomes, and cannot establish whether citation differences reflect true differences in scientific merit. The authors conclude that journal-impact inequalities should be considered when making citation-based comparisons between therapeutic fields.
Unknown journal · Jun 2026DOI ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (recruiting). This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and part
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered Phase 1/Phase 2 interventional trial (not yet recruiting). Duchenne Muscular Dystrophy (DMD) is a rare, genetic disease that leads to muscle weakness, breathing difficulties, heart disease, and early death. Approximately half of individuals with DMD have elevated body mass indices (BMIs) in the overweight or obesity range. High BMI is due to a combination of factors including limited mobility and steroid medications, which are used to treat DMD. There are new medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that promote weight loss in the general population. GLP-1
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (enrolling by invitation). The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are: 1. Is obesity medication usage is associated with reduced body mass index (BMI) and weight? 2. Is obesity medication usage is associated with reduced utilization of emergency department and inpatient care or obesity-related conditions over time? 3. Is obesity medication
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered N/A interventional trial (recruiting). Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatr
ClinicalTrials.gov · Jun 2026View trial ↗ InsufficientPreprint
This paper presents a theoretical hypothesis arguing that current GLP-1 and dual GIP/GLP-1 receptor agonist therapies (e.g., semaglutide, tirzepatide) produce weight loss plateaus because they only address one side of what the authors term the "mass balance equation" — net mass inflow (NMI) — while net mass outflow (NMO) passively and actively declines over time. The authors propose a "mass balance model" (MBM) as an alternative explanatory framework to the conventional energy balance model, framing the plateau as a predictable physical consequence rather than a vague compensatory metabolic adaptation. Based on this framework, the authors hypothesize that combining an NMI-reducing agent with an NMO-stabilizing or NMO-enhancing agent could produce greater, more durable weight loss and improved body composition. Candidate NMO-targeting agents discussed include SGLT2 inhibitors, activin/myostatin pathway inhibitors, and mitochondrial uncouplers. The paper is entirely theoretical; no original experimental data, clinical trials, or systematic evidence synthesis are presented. Its primary limitation is that the MBM framework and the dual-action hypothesis remain untested in human or animal studies.
Unknown journal · Jun 2026DOI ↗ Insufficient
This News and Perspectives article, published in JMIR, examines the intersection of US policy changes and the growth of digital health platforms as factors influencing the affordability and accessibility of GLP-1 receptor agonist medications for obesity. The piece discusses how emerging access models—combining policy reform with telehealth and online pharmacy platforms—may expand patient access to these treatments, which have historically been cost-prohibitive for many individuals. As a journalistic and opinion-oriented piece rather than an original empirical study, it does not present primary data, clinical trial results, or systematic evidence. It instead contextualizes current trends and speculates on potential implications for the healthcare landscape. Key limitations include the absence of original research data, no patient outcomes measured, and an inherently perspective-driven framing. Readers should note that the article reflects one correspondent's analysis of a rapidly evolving policy and commercial environment, and conclusions about real-world impact on patient outcomes remain untested at this stage.
Journal of medical Internet research · Jun 2026DOI ↗ Insufficient
This scoping review, conducted following PRISMA-ScR guidelines, examines whether GLP-1 receptor agonists (GLP-1 RAs) — including semaglutide, liraglutide, tirzepatide, and retatrutide — may interfere with autologous fat grafting outcomes. The authors note that millions of patients using GLP-1 RAs for weight loss now present to aesthetic surgeons with facial volume loss and soft tissue deflation, conditions commonly treated with fat grafting. The review synthesizes preclinical and clinical evidence on how GLP-1 RA medications affect adipocyte biology, adipose-derived stem cell (ASC) function, and tissue revascularization. The authors identify several theoretical interference points: GLP-1-mediated adipocyte "browning" and thermogenic activation (including UCP1 upregulation), enhanced lipolysis via ATGL and HSL pathways, suppression of white adipogenic differentiation in ASCs favoring beige/thermogenic lineages, and altered angiogenic and inflammatory signaling during the revascularization window critical to graft survival. The authors explicitly acknowledge that no clinical or preclinical studies have directly examined fat graft outcomes in patients receiving these therapies. The review's conclusions are framed as hypothesis-generating, and any clinical considerations offered are described as mechanism-based rather than evidence-based. This limits the paper's direct applicability to patient care.
Aesthetic surgery journal · Jun 2026DOI ↗ Insufficient
SYNCHRONIZE-JP is an ongoing 76-week, randomized, double-blind, parallel-group, multicenter Phase 3 clinical trial evaluating survodutide — a novel dual glucagon receptor/GLP-1 receptor agonist — for obesity disease management in Japanese adults. The study enrolled 274 participants aged ≥18 years with obesity and at least one qualifying complication (type 2 diabetes capped at 30%, hypertension, or dyslipidemia). Participants were randomized 1:1:1 to one of two doses of once-weekly survodutide or placebo, alongside a reduced-calorie diet and increased physical activity. At baseline, the mean age was 53.1 years, mean BMI was 33.2 kg/m², 47.8% were female, and 24.1% had type 2 diabetes; the most common comorbidities were dyslipidemia (81.4%) and hypertension (72.6%). The co-primary endpoints are percentage change in body weight and proportion achieving ≥5% body weight reduction from baseline to Week 76. A subset will also be assessed for liver fat content and body composition. This publication reports only the trial rationale, design, and baseline characteristics; no efficacy or safety outcome data are yet available, which is a key limitation.
Diabetes, obesity & metabolism · May 2026DOI ↗ Insufficient
This News and Perspectives article, authored by JMIR Correspondent Anna Zucker, examines the landscape of GLP-1 receptor agonist prescribing through telehealth platforms for obesity management. The piece highlights a structural concern: while digital health platforms have significantly expanded access to GLP-1 medications, they may not consistently provide adequate clinical follow-up and ongoing support after the initial prescription is issued. The article argues that this "clinical support gap" — encompassing monitoring, behavioral counseling, and longitudinal care — could undermine the potential benefits of these medications and may pose risks to patients. As a News and Perspectives piece, the article does not present original empirical data or a clinical trial; rather, it synthesizes observations and commentary to frame an emerging issue in digital health delivery. Its limitations include the absence of primary data, quantitative analysis, or a systematic review methodology. The piece is best interpreted as expert opinion and advocacy for improved care structures within telehealth-based GLP-1 treatment models, rather than as direct clinical evidence.
Journal of medical Internet research · May 2026DOI ↗ Insufficient
This brief report, authored for nurse practitioners (NPs), examines the clinical and regulatory challenges arising from patient-driven "microdosing" of GLP-1 receptor agonists (semaglutide and tirzepatide) in the context of FDA restrictions on compounded versions following resolution of drug shortages. The authors describe how affordability barriers push patients toward subtherapeutic dosing strategies, unregulated "research-grade" peptides purchased online, and unsupervised sources such as medical spas. The paper outlines specific safety concerns associated with these practices, including pen manipulation, medication sharing, compounded vials, and dosing errors, as well as the side effect profiles encountered. It also explores how provider weight bias may inadvertently drive patients toward unregulated alternatives and offers practical stigma-reduction strategies for clinical encounters. The authors discuss the legal risks of compounded "copies" and acknowledge a narrow legitimate role for compounding in patients with documented allergies. As a brief report rather than an empirical study, the paper does not present original data or a systematic review; its conclusions are based on regulatory context, clinical observation, and expert opinion. Its primary value lies in synthesizing emerging practice-relevant issues for NPs navigating a rapidly evolving regulatory environment.
Journal of the American Association of Nurse Practitioners · May 2026DOI ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (recruiting). Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
ClinicalTrials.gov · May 2026View trial ↗